Figure 3.

Stratification into double homozygous carriers (FCGR3A 158 V/V; FCGR2A 131 H/H, designated V/V^3A‐H/H^2A and FCGR2A 158 F/F; FCGR2A 131 R/R, designated F/F^3A‐R/R^2A). (A) Fcγ receptor polymorphism frequency distribution for double homozygous carriers V/V^3A‐H/H^2A and F/F^3A‐R/R^2A within the study cohort of 85 RR‐MS patients previously treated with alemtuzumab. (B) Clinical and radiological characteristics of double homozygous RR‐MS patients after alemtuzumab therapy (n = 21) stratified by high‐ (V/V^3A‐H/H^2A) and low‐affinity (F/F^3A‐R/R^2A) FcγR polymorphisms. For some characteristics not all patient data was available. For the following analyses the n was: 20, NEDA‐3 (1 patient missing, F/F^3A‐R/R^2A group); 20, MRI stability (1 patient missing, F/F^3A‐R/R^2A group). The remaining analyses were carried out on all 21 patients. Shown are percentages of the respective genotypic groups as bargraphs and absolute numbers of patients in white. Statistical analysis: Two‐sided Fischer’s exact test was applied on absolute patient numbers. A p‐value < .05 was considered statistically significant. Abbreviations: CDP, confirmed disability progression; MRI, magnetic resonance imaging; NEDA, no evidence of disease activity; IAR, infusion‐associated reactions; SAD, secondary autoimmune disease.